2-year survival data from a randomized study of peginterferon alfa-2a (40KD) vs interferon alfa-2a in patients with chronic-phase chronic myelogenous leukemia.

被引：0
|
作者：
Lipton, JH
Khoroshko, ND
Golenkov, AK
Abdulkadyrov, KM
Nair, MK
Raghunadharao, D
Brummendorf, T
Bergstrom, B
机构：
[1] Princess Margaret Hosp, Allogene BMT Program, Toronto, ON M4X 1K9, Canada
[2] Hematol Res Ctr, Dept Leucosis, Chemotherapy & Pathol Erithron, Moscow, Russia
[3] Moscow Regional Res Clin Inst, Dept Hematol Immunol, Moscow, Russia
[4] Russian Sci Res Inst Hematol & Transfusiol, Dept Hematol, St Petersburg, Russia
[5] Reg Canc Ctr, Dept Med Oncol, Trivandrum 695011, Kerala, India
[6] Nizams Inst Med Sci, Dept Med Oncol, Hyderabad, Andhra Pradesh, India
[7] Univ Tubingen, Med Klin Poliklin, Dept Hematol Oncol Immunol & Rheumatol, Tubingen, Germany
[8] Hoffmann La Roche Inc, Nutley, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3363
引用
收藏
页码：904A / 904A
页数：1
相关论文
共 50 条
  • [21] Peginterferon alfa-2a in patients with chronic hepatitis C
    Zeuzem, S
    Feinman, SV
    Rasenack, J
    Heathcote, EJ
    Lai, MY
    Gane, E
    O'Grady, J
    Reichen, J
    Diago, M
    Lin, A
    Hoffman, J
    Brunda, MJ
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (23): : 1666 - 1672
  • [22] ALT flares in patients with HBeAg-positive chronic hepatitis B and treated with either conventional interferon alfa-2a or peginterferon alfa-2a (40KD) (PEGASYS®) are not necessary for a significant response to therapy.
    Cooksley, WGE
    Lai, MY
    Piratvisuth, T
    Wang, YJ
    Mahachai, V
    Chao, YC
    Tanwandee, T
    Chutaputti, A
    Chang, WY
    Zahm, FE
    Pluck, N
    HEPATOLOGY, 2003, 38 (04) : 724A - 724A
  • [23] Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naive patients with chronic hepatitis C: a randomized, controlled study
    Bruno, R.
    Sacchi, P.
    Scagnolari, C.
    Torriani, F.
    Maiocchi, L.
    Patruno, S.
    Bellomi, F.
    Filice, G.
    Antonelli, G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (03) : 369 - 376
  • [24] The cost effectiveness analysis of treatment with peginterferon alfa-2a (40KD) in patients with hbeag-negative chronic hepatitis B
    Kowalik, E.
    Niewada, M.
    Jakubczyk, M.
    Horban, A.
    Berak, H.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2006, 9 (06) : A300 - A300
  • [25] A cost utility analysis of peginterferon alfa-2a (40KD) versus peginterferon alfa-2b (12KD) for the treatment of chronic hepatitis C (CHC) in the UK
    Latimer, NR
    Lewis, GJ
    VALUE IN HEALTH, 2005, 8 (06) : A58 - A58
  • [26] Efficacy of peginterferon alfa-2a (40KD) and ribavirin in patients with chronic hepatitis C in Germany -: A contribution to health care research
    Zehnter, E
    Mauss, S
    John, C
    Heyne, R
    Möller, B
    Bokemeyer, B
    Moog, G
    Alshuth, U
    Hüppe, D
    HEPATOLOGY, 2005, 42 (04) : 683A - 683A
  • [27] Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C
    van Leusen, Robert
    Adang, Rob P. R.
    de Vries, Richard A.
    Cnossen, Trijntje T.
    Konings, Constantijn J. A. M.
    Schalm, Solko W.
    Tan, Adriaan C. I. T. L.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (02) : 721 - 725
  • [28] Peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin is an efficacious and safe treatment for chronic hepatitis C in patients with cirrhosis.
    Marcellin, P
    Brillanti, S
    Cheínquer, H
    Cooksley, WGE
    Shiffmann, ML
    Schmidt, WE
    Brunda, M
    HEPATOLOGY, 2002, 36 (04) : 576A - 576A
  • [29] Peginterferon Alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1
    Jeffers, LJ
    Cassidy, W
    Howell, CD
    Hu, S
    Reddy, KR
    HEPATOLOGY, 2004, 39 (06) : 1702 - 1708
  • [30] Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1
    Pijak, MR
    Gazdik, F
    Hrusovsky, S
    HEPATOLOGY, 2004, 40 (03) : 760 - 761
12345